BeOne Medicines Ltd. (ONC) Earnings
BeOne Medicines Ltd. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $1.66. ONC has beaten EPS estimates in 4 of its last 6 reported quarters (average surprise +57.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.73 | $1.96 | +168.5% | $1.5B | +2.5% |
| Feb 26, 2026 | $1.60 | $0.59 | -63.4% | $1.5B | +5.2% |
| Nov 6, 2025 | $0.72 | $1.09 | +51.4% | $1.4B | -2.7% |
| Aug 6, 2025 | $0.48 | $0.84 | +75.0% | $1.3B | -8.8% |
| May 7, 2025 | $-0.71 | $1.22 | +271.8% | $1.1B | -10.4% |
| Feb 27, 2025 | $-0.88 | $-1.43 | -62.5% | $1.1B | +8.5% |
| Mar 30, 2024 | — | $-2.41 | — | $752M | — |
| Dec 30, 2023 | — | $-25.53 | — | $634M | — |
| Sep 29, 2023 | — | $2.01 | — | $781M | — |
| Mar 31, 2023 | — | $-3.34 | — | $448M | — |
| Jun 29, 2019 | — | $-1.43 | — | $243M | — |
| Mar 30, 2019 | — | $-2.81 | — | $78M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
John Euler highlighted Brukinza's strong commercial and clinical progress with first-quarter sales of 1.1 billion and 38% growth. Sonro and BTK-CDAC are progressing. Lai Wang discussed pipeline progress in hematology, including Bokinsa's phase III study and BTK-CDAC advance, and in solid tumors, such as Devambra's U.S. priority review, CDK4 inhibitor progress, and GPC341BB bispecific enrollment in a potentially pivotal HCC study, along with selective external innovation
Guidance
The 2026 revenue guidance is raised to $6.3 billion to $6.5 billion, an increase of $100 million across the range. GAAP gross margin remains in the high 80% range. GAAP operating expense expectations stay between $4.7 billion and $4.9 billion. GAAP operating income estimates are updated to between $750 million and $850 million
Segment performance
Product revenue reached $1.5 billion in Q1, up 34% year-over-year. Brukinza global revenues totaled $1.1 billion, a 38% year-over-year growth. In the U.S., Brukinza's Q1 sales were 761 million, driven by approximately 28% volume growth compared to Q1 2025. Tevimbra saw a 20% increase with sustained market leadership in China, and about half of its growth came from markets outside China. InLicense and other products grew 27% year-over-year. XGiva had $90 million in revenue. Sunratoclax had a good reception in China. Gross margin improved to 89% from around 85% in the prior year. Operating expenses grew 16% to $1.1 billion. Income from operations was $250 million, net income was $227 million, and free cash flow was $161 million. The 2026 revenue guidance was raised to between $6.3 billion to $6.5 billion, an increase of $100 million across the range
Analyst Q&A
Q: Miguel Nachovenbevich inquired about Brukinza vs competitor's claims,
A: Amit Agarwal discussed IRC data and study conduct principles.
Q: Kalpit Patel asked about Celestial TN-CLL trial UMRD and CDAC efficacy hurdle,
A: John Euler talked about study setup and benchmark.
Q: Jessica Five asked about Brukinza's launch in Europe and CDAC launch ramp,
A: John Euler and others spoke about Europe launch and CDAC launch plans.
Q: Leonid Timoshev asked about immunology programs,
A: Lai Wang talked about CSU phase two and IRAC4 discontinuation.
Q: Zee Chen asked about PD1 VGF CTLA-4 trispecific,
A: Lai Wang discussed molecule differentiation.
Q: Gregory Renza asked about guidance and net pricing,
A: Aaron Rosenberg talked about growth and net pricing.
Q: Michael Schmidt asked about GPC 341BB and HCC pivotal study,
A: Mark Lanassa talked about data.
Q: Rennie Benjamin asked about Sonroclax launch in China and U.S. competition,
A: Xiaobin Wu and others talked about China launch and U.S. impact.
Q: Yaron Werber asked about AV traction and CDK4 inhibitor at ASCO,
A: Mark Lanassa talked about AV and CDK4 data.
Q: Sean Laman asked about operating leverage,
A: Aaron Rosenberg talked about growth and operating leverage